Evidence map›Paper›PMID 32614159›Full record

Trial reportCancer science2020

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.

Takashi Kumagai, Chiaki Nakaseko, Kaichi Nishiwaki, Chikashi Yoshida, Kazuteru Ohashi, Naoki Takezako, Hina Takano, Yasuji Kouzai, Tadashi Murase, Kosei Matsue and 6 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Takashi KumagaiDepartment of Hematology, Ome Municipal General Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6850-4545
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Kaichi NishiwakiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Kashiwa Hospital, Chiba, Japan.
Chikashi YoshidaDepartment of Hematology, National Hospital Organization, Mito Medical Center, Higashiibarakigun, Japan.
Kazuteru OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Naoki TakezakoDepartment of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan.
Hina TakanoDepartment of Hematology, Musashino Red Cross Hospital, Musashino, Japan.
Yasuji KouzaiDepartment of Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo, Japan.
Tadashi MuraseDepartment of Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
Kosei MatsueDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.ORCID https://orcid.org/0000-0002-8669-9865
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Junichi SakamotoTokai Central Hospital, Kakamigahara, Japan.
Hisashi WakitaDivision of Hematology and Oncology, Japanese Red Cross Society, Narita Red Cross Hosp, Narita, Japan.
Hisashi SakamakiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Koiti InokuchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kanto CML, Shimousa Hematology Study Groups
Tokyo Metropolitan Komagome Hospital · JPChiba University Hospital · JPDokkyo Medical University Saitama Medical Center · JPJapanese Red Cross Narita Hospital · JPJikei University School of Medicine · JPKameda Medical Center · JPKyoto University · JPMusashino Red Cross Hospital · JPNational Hospital Organization · JPNational Hospital Organization Mito Medical Center · JPNippon Medical School · JPOme Municipal General Hospital · JPTokai Central Hospital · JPTokyo Metropolitan Tama Medical Center · JP

Funding

Bristol-Myers Squibbthe Epidemiological and Clinical Research Information Network (RCRIN)
6 · The paper itself

Abstract

This study presents the final report of the multicenter, prospective tyrosine kinase inhibitor discontinuation study, D-STOP, after a 3-year follow-up of 54 patients with chronic CML who discontinued dasatinib after a sustained deep molecular response (DMR) for ≥2 years with dasatinib treatment. Estimated treatment-free remission (TFR) rates at 12 and 36 months were 63.0% [95% confidence interval (CI): 48.7-74.3] and 59.3% (95% CI: 45.0-71.0), respectively. CD3

Indexed as

Killer Cells, NaturalT-Lymphocytes, CytotoxicAdultAgedAged, 80 and overDasatinibFemaleFollow-Up StudiesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte CountMaleMiddle AgedProspective StudiesProtein Kinase InhibitorsRemission InductionDasatinibProtein Kinase InhibitorsCMLdasatinibNKstopTKI

Identifiers

PMID32614159
PMCPMC7419041
OpenAlexW3033935772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.